

PIPELINE

Our aim is to develop the right antibody for the right target, ultimately producing a treatment that is safer and more effective for patients with Alzheimer's disease.

The first of its kind to enter the clinic, sabirnetug, an immunotherapy drug candidate, is designed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer's-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of Alzheimer's disease by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function.

Sabirnetug (ACU193) Formulation	Indication	Discovery/Preclinical Research	Clinical Research Phase 1	Phase 2	Phase 3	Upcoming Milestone
Intravenous (IV) Infusion	Early Alzheimer's disease					Ph 2 initiating 1H 2024
Subcutaneous (SC)	Early Alzheimer's disease					Ph 1 initiating mid-2024

ALTITUDE-AD

NCT identifier NCT06335173

This study is a Phase 2, double-blind, randomized, placebo-controlled adaptive design trial to evaluate the efficacy and safety of intravenous sabirnetug (ACU193) in early Alzheimer's disease.

LEARN MORE >

INTERCEPT-AD

NCT identifier NCT04931459

This study is a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and tolerability, and to establish the clinical proof of mechanism, of sabirnetug (ACU193) in patients with early Alzheimer's disease.

LEARN MORE >